Mesothelioma | Mesothelioma

... PharmaLive: AVEO Pharmaceuticals Appoints John Ryan, Ph.D., M.D., as Chief Medical Officer TODAY ON PHARMALIVE.COM AVEO Pharmaceuticals Appoints John Ryan, Ph.D., M.D., as Chief Medical Officer Dr.

Ryan's Expertise in Translational Medicine a Key Addition as AVEO Moves its Portfolio of Novel Cancer Medicines Forward into the Clinic CAMBRIDGE, Mass., March 30, 2006 /PRNewswire/ - AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel cancer medicines, announced today that John L.

Ryan, Ph.D., M.D., has joined the company as Chief Medical Officer.

Dr.

Ryan will be responsible for clinical strategy and development of AVEO's pipeline, including AV-412, a novel dual kinase inhibitor scheduled to enter the clinic by the middle of this year.

Dr.

Ryan brings almost 20 years of experience in drug discovery and development to AVEO, including expertise in translational medicine and cancer biology.

He joins the company after 11 years at Wyeth where he most recently held the position of Senior Vice President of Translational Research.

In 2001, he was appointed head of the new Department of Experimental Medicine, which was created to explore new technologies such as pharmacogenomics in exploratory clinical trials, to work closely with FDA on clinical pharmacogenomics, and to bridge discovery and development with the creation of new biomarkers.

In 1998, he was promoted to Senior Vice President of Clinical Research & Development and assu...

Read more...